Comparative Risk for Angioedema Associated with the Use of Drugs that Target the Renin-Angiotensin-Aldosterone System

    Basic Details
    Date
    Monday, November 12, 2012
    Type
    Publication
    Medical Product
    aliskiren
    angiotensin II receptor blocker (ARB)
    angiotensin-converting enzyme (ACE) inhibitor
    Health Outcome(s)
    angioedema
    Description

    This article describes a Mini-Sentinel protocol-based one-time assessment of the risk of angioedema associated with new use of drugs that act on the renin-angiotensin-aldosterone system (RAAS), including angiotensin converting enzyme inhibitors (ACEIs), angiotensin II receptor blockers (ARBs), and aliskiren.

    Information
    Time Period
    2001 - 2010
    Population / Cohort
    All individuals 18 years of age or older
    Data Source(s)
    Mini-Sentinel Distributed Database (MSDD)
    Author(s)

    Sengwee Toh ScD; Marsha E. Reichman PhD; Monika Houstoun PharmD; Mary Ross Southworth PharmD; Xiao Ding PhD; Adrian F. Hernandez MD; Mark Levenson PhD; Lingling Li PhD; Carolyn McCloskey MD, MPH; Azadeh Shoaibi MS, MHS; Eileen Wu PharmD; Gwen Zornberg MD, MS, ScD; Sean Hennessy PharmD, PhD

    Corresponding Author

    S. Toh, Department of Population Medicine, Harvard Pilgrim Health Care Institute and Harvard Medical School, 401 Park Drive, Suite 401 East, Boston, MA 02215, USA. Email: darren_toh@harvardpilgrim.org